Asian groups to create $150 million Sino-Singapore Healthcare Fund

25 June 2019

Asian healthcare platform Novena Global Lifecare Group is to join with two other groups to create the Sino-Singapore Healthcare Fund with a target size of $150 million.

The creation of the fund, which will primarily invest in a portfolio of companies involved in medical services, biomedical projects, mature drugs and precision medicine in Southeast Asia, has been announced as Sinopharm Capital and Cedarlake Capital Group make investments into Novena.

"Sinopharm Capital has abundant resources in China's pharmaceutical industry"Sinopharm Capital is a private equity arm of China National Pharmaceutical Group Corporation. The investment into Novena Global Lifecare is its first-ever investment in a Singapore healthcare company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK